Investors File Securities Fraud Lawsuit Against GeneDx Holdings Corp.
A federal class action lawsuit has been initiated against GeneDx Holdings Corp. following a sharp decline in the company's share price. Investors who purchased WGS common stock between April 16, 2025, and May 4, 2026, are now eligible to seek lead plaintiff status in the case, which centers on alleged misrepresentations regarding an acquisition.
The complaint, filed in the United States District Court for the District of Connecticut under Taher Basma v. GeneDx Holdings Corp., claims the company misled shareholders concerning its acquisition of Fabric Genomics. GeneDx had touted the 2025 deal as a strategic move to integrate AI-driven genomic interpretation and generate recurring revenue. However, the lawsuit alleges that defendants failed to disclose significant viability issues regarding Fabric.
The discrepancy surfaced on May 4, 2026, when GeneDx reported its first-quarter results. The company revealed a substantial drop in adjusted gross margins and disclosed a $31.3 million impairment loss tied to Fabric—nearly the entire amount of the initial cash investment. Following this announcement, the company's stock price plummeted by more than 49 percent.
Investors seeking to participate in the litigation have until August 3, 2026, to file for lead plaintiff status. Legal firm Kessler Topaz Meltzer & Check, LLP is currently offering case evaluations for affected shareholders. Participation in the lawsuit does not require upfront costs, as representation is handled on a contingency basis.
Comments (0)
No comments yet. Be the first!